Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group S. p. A.

Q2 2026 Earnings Call Summary Moby Intelligence Wed, August 5, 2026 at 3:38 AM GMT+2 3 min read NVDA STVN Stevanato Group S. p. A.

Q2 2026 Earnings Call Summary - Moby Strategic Performance and Market Positioning Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Revenue growth of 8% was driven by a 9% increase in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, offsetting a slight decline in Engineering. High-value solutions (HVS) grew 16% year-over-year, now representing 45% of total revenue, fueled by a 30% surge in biologics demand. Management completed the divestiture of Balda C.

Brewer to optimize the corporate footprint and focus resources on complex, integrated drug delivery systems. The proprietary Alina variable dose pen platform achieved a major commercial milestone with regulatory approval in several European countries for liraglutide-based therapies. The Engineering segment showed operational stabilization with gross margins expanding 540 basis points due to business optimization initiatives and a refreshed project portfolio.

GLP-1 therapies currently represent approximately 22% to 23% of total company revenue, serving as a durable long-term tailwind for the injectable market. Strategic focus remains on the global drug pipeline where over 60% of the 9,000 injectable assets under evaluation are biologics. Growth Initiatives and Guidance Assumptions Full-year 2026 revenue guidance was adjusted to EUR 1.

260 billion to EUR 1. 280 billion, accounting for a EUR 15 million headwind from the Balda divestiture. The Fishers facility is on track for commercial production later this year, with a planned full ramp-up of operations expected by the end of 2028.

Management expects the Alina platform to generate double-digit revenue growth in coming years as North American regulatory approvals are anticipated in late 2026. The next-generation RTU 400 cartridge line in Latina is slated for installation in the next few months, with commercial production targeted for 2027. Guidance assumes high-value solutions will reach 47% to 48% of total revenue for the fiscal year, driven by continued biologics and GLP-1 momentum.

Structural Changes and Financial Adjustments Recorded a one-time expense of EUR 12. 2 million related to the sale of the Balda C. Brewer subsidiary in California.

The effective tax rate for 2026 is expected to be higher at 28. 2% due to the expiration of prior Italian tax incentives and the impact of the divestiture. Variable compensation tied to a specific customer contract provided protection against volume reductions, compensating for capacity reservation and missing margins.

Currency headwinds for the full year are now estimated at EUR 10 million, a favorable revision from the initial EUR 18 million projection. Story Continues Q&A Session Highlights BDS growth outlook adjustment and organic performance drivers One stock. Nvidia-level potential.

30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management clarified that while reported growth was adjusted to high single digits, organic growth remains in the double digits. The adjustment reflects a EUR 15 million headwind from the divestiture partially offset by EUR 8 million in favorable currency translation. Strategic significance of the Alina platform regulatory approval The approval validates eight years of R&D and shifts the company from a CMO model to a proprietary IP provider in the 'Champions League' of drug delivery.

The platform uses an 'integrated system approach' combining Stevanato's proprietary glass cartridges with the delivery device. Engineering segment recovery and sales cycle dynamics Optimization efforts are yielding results, but management remains cautious as sales cycles are currently longer than in previous years. New order wins are increasing, particularly for visual inspection machines in Europe and Asia, supporting a return to historical margins by 2027.

Market penetration and patient adoption of GLP-1 therapies Management views the current GLP-1 market as the 'tip of the iceberg' with less than 10% patient penetration of the 1. 5 billion addressable population. The company is actively pursuing validation for biosimilar versions of GLP-1s to capture market share as original patents expire.